Disclosures for "Real-world Evidence of Efficacy, Use, and Discontinuation of Pharmacotherapies for the Treatment of Essential Tremor"
-
Ms. Gerbasi has received personal compensation for serving as an employee of Sage Therapeutics, Inc.. Ms. Gerbasi has stock in Sage Therapeutics. Ms. Gerbasi has received intellectual property interests from a discovery or technology relating to health care.
-
Ms. Tu has received personal compensation for serving as an employee of Medicus Economics, LLC.
-
Mrs. Chertavian has nothing to disclose.
-
Miss Nejati has received stock or an ownership interest from Biogen.
-
Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda Therapeutics. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for US WorldMeds LLC. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin Inc. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe-NeuroDerm Neuropharma. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bukwang Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. LeWitt has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for CLINICAL NEUROPHARMACOLOGY.